Moderna launched RSV vaccine mResvia in 2024 as the third-to-market product behind GSK and Pfizer vaccines ... and competing technologies could prove safer and more effective.

Another exciting area of personalized medicine is using nanotechnology for gene therapy. Gene therapy involves altering or ...

The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health ...

Leerink Partners analyst Mani Foroohar has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Invest with ...

Moderna's mRESVIA joined the market after RSV vaccines from Pfizer and GSK already had established themselves. At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $ ...

The Moderna and Pfizer agreements include options for a total of 600 million doses, 300 million apiece, but these can only be exercised with additional funding from Congress, according to HHS.

Moderna’s mRNA shot, mRESVIA, only generated $10 million in sales during the third quarter, its RSV season debut. Besides the impact of a narrowed CDC policy, RSV incumbents GSK and Pfizer ...

Moderna stock (MRNA) fell over 9% on Wednesday ... with London-based pharma giant GlaxoSmithKline (GLAXO.BO). Pfizer stock (PFE) ticked up a much more modest 0.9%, while GSK itself dropped ...

Moderna’s stock rose 11.6 per cent, Novavax gained 10.8 per cent and CureVac’s shares advanced 5 per cent. Shares in Pfizer, one of the biggest US drugmakers, added nearly 1 per cent.

Apart from the CDC’s restrictive recommendation, mRESVIA also faces the unenviable task of going up against incumbent RSV shots from GSK and Pfizer. Following news of Moderna’s cost-cutting ...